Category ABOUT

PIER MARIA FORNASARI
2026-09-01

Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III Relapsing Multiple Sclerosis trials

Novartis announced positive topline results from its Phase III REMODEL-1/-2 trials of remibrutinib in relapsing multiple sclerosis.1 Remibrutinib, a highly selective and potent oral Bruton’s tyrosine kinase (BTK) inhibitor, demonstrated superiority versus teriflunomide in reducing annualized relapse rate (ARR) and inflammatory brain lesions with a favorable safety profile. The results of the REMODEL trials establish remibrutinib

Read More

No Comments InCLINICAL TRIALS
PIER MARIA FORNASARI
2026-08-18

Researchers find cold-stored platelets safe and effective in cardiac surgery up to 21 days

CHIP trial extends shelf life compared with conventional room-temperature storage Key Takeaways Extending the shelf life of platelets with refrigeration didn’t hurt their hemostatic function for people undergoing complex cardiac surgery, the landmark CHIPS trial found. Platelets stored at 1-6°C (33.8-42.8°F) for up to 21 days were noninferior to platelets stored up to 7 days

Read More

No Comments InCLINICAL TRIALS
PIER MARIA FORNASARI
2026-04-22

CAR-T cells trials efficacy presented at the America Association for Cancer Research annual meeting

The third Clinical Trials Plenary Session at the AACR Annual Meeting 2026 was dedicated to “Cellular Therapies and Complex Immunotherapies” and provided updates on sophisticated immunotherapeutic CAR-T cells strategies, with special emphasis on their application for solid tumors.  Can CAR T-cell therapy intercept disease in patients with smoldering myeloma? The first presenter Omar Nadeem, MD, of

Read More

No Comments InCAR-T CLINICAL TRIALS
PIER MARIA FORNASARI
2026-03-12

Safer blood clot treatment with apixaban than with rivaroxaban, according to large venous thrombosis trial

The first clinical trial to compare two commonly used drugs head-to-head for venous thrombosis treatment has found a clear winner: while both drugs work well to prevent recurrent blood clots, apixaban is safer than rivaroxaban, with fewer bleeding complications. Venous thrombosis occurs when a blood clot lodges in the veins of the legs or lungs.

Read More

No Comments InCLINICAL TRIALS
PIER MARIA FORNASARI
2026-01-17

First-in-human new liver- and gut-targeted oral drug trial lowers high blood fats

In a Phase 1 clinical study, researchers led by EPFL and their partners report that a new liver- and gut-targeted oral drug can safely lower triglycerides and other blood lipids. When we eat, our bodies convert extra calories, especially from carbs, sugar, fats, and alcohol, into molecules called “triglycerides”. Triglycerides are a form of fat

Read More

No Comments InCLINICAL TRIALS
PIER MARIA FORNASARI
2025-01-31

Study Finds Three New Safe, Effective Ways To Treat Drug-Resistant Tuberculosis

New options make care faster, safer, and more accessible At a glance: Tuberculosis remains one of the top infectious disease killers worldwide, a challenge amplified by drug-resistant forms of the disease. Now, in a major step forward, an international clinical trial has found three new safe and effective drug regimens for tuberculosis that is resistant to

Read More

No Comments InCLINICAL TRIALS
PIER MARIA FORNASARI
2025-01-31

FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain

First Drug Approved in New Class of Non-Opioid Pain Medicines; Agency Continues to Take Steps to Support New Approaches for Pain Management the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx reduces pain by targeting a pain-signaling

Read More

No Comments InCLINICAL TRIALS
PIER MARIA FORNASARI
2024-12-07

New drug provides first boost to asthma attack treatment in 50 years

A team of international researchers has found a drug injected under the skin effectively treats asthma and chronic obstructive pulmonary disease and reduces the need for further treatment. Dr Sanjay Ramakrishnan, from UWA’s Medical School and the Institute for Respiratory Health, was lead author of the paper published in The Lancet Respiratory Medicine. “Asthma and chronic

Read More

No Comments InCLINICAL TRIALS
PIER MARIA FORNASARI
2024-10-25

At-home transcranial direct brain stimulation for depression is safe and effective, according to research from UTHealth Houston, King’s College London, and University of East London

A device that delivers direct stimulation to the brain was found to be a safe and effective means of treating depression at home, according to a new study by researchers at UTHealth Houston; the Institute of Psychiatry, Psychology & Neuroscience at King’s College London; and the University of East London. The research was published in Nature

Read More

No Comments InCLINICAL TRIALS